Skip to content

Targeted Transcriptomic Profiling Identifies Biomarkers and Molecular Features Associated With Immunotherapy Response in Classic Hodgkin Lymphoma.

Aug 2026 · Modern Pathology · Vol 39, pp. 101060 · 0 citations · 98 references
Medicine

TL;DR

The biological complexity and transcriptional diversity underlying CHL and its tumor microenvironment is highlighted, with an "oncogene-driven" transcriptional profile independent of previous treatment status, whereas responders showed an "inflammatory immune-scape" phenotype, offering insight into mechanisms of resistance.

Abstract

Classic Hodgkin lymphoma (CHL) is a highly curable disease. However, a subset of patients develops relapsed/refractory disease, underscoring the need for predictors of treatment response. Although immune-checkpoint inhibitors have improved outcomes, many patients still experience suboptimal responses. A deeper understanding of the CHL transcriptomic landscape may improve patient stratification and guide treatment approaches. Targeted mRNA-NGS was performed on formalin-fixed paraffine-embedded CHL-tissue using the HTG EdgeSeq Precision Immune-Oncology Panel (1,392 genes) in treatment-naive and post-chemotherapy relapsed treated with nivolumab-based protocols. Differential gene expression and pathway enrichment analyses were conducted to characterize tumor-intrinsic, and microenvironmental features associated with disease biology and treatment response. Across all CHL samples (n = 25) we observed overexpression of immune-checkpoint and immunoregulatory genes (CD274, CTLA-4, IL6, IL13), and markers of macrophage-rich/matrix-remodeling microenvironment (CD163, MMP2, TIMP1), alongside loss of B-cell identity and tumor suppression programs. Pathways analysis revealed activation of IL6/JAK/STAT3, TNF-α/NF-κB, KRAS-UP, and Inflammatory response, with reduced proliferative and metabolic activity. Immunotherapy non-responders, both in the overall (n = 5; 20%), and the treatment-naïve CHL (n = 2; 12%) displayed a proliferative, cytokine-activated, and immunologically cold phenotype. This includes shared overexpression of FADD, NFKB1, and TGFB1 and downregulation of SMAD7, together with activation of E2F, G2M, MYC, and PI3K/AKT/mTOR pathways and negative enrichment of TNF-α/NF-κB, IL6/JAK/STAT3, and Inflammatory response. Post-chemotherapy relapsed (n = 8) exhibited adaptative immunoregulatory and stress response signatures (IL15, TNFSF18, MAPK8, FUT4), along with reduced immune activation and loss of tumor-suppressor signaling. This study highlights the biological complexity and transcriptional diversity underlying CHL and its tumor microenvironment. Immunotherapy non-responders exhibited an "oncogene-driven" transcriptional profile independent of previous treatment status, whereas responders showed an "inflammatory immune-scape" phenotype, offering insight into mechanisms of resistance. Despite the limited sample size, these findings provide a foundation for larger precision-focused studies aimed at improving outcomes in CHL.

View source

Similar papers

Open access Sep 2026

63 Th17 Signature Predicts Response to Dual Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Abstract Background Combination immune checkpoint inhibition with anti-CTLA-4 and anti-PD-1 antibodies improves outcomes in metastatic renal cell carcinoma (mRCC), yet 40–60% of patients fail to achieve meaningful responses. Robust biomarkers that predict deep and durable responses are lacking. We aimed to define syste...

S. Guglietta, A. Bärenwaldt, Anthony Sonrel et al. · 0 citations
Open access Aug 2026

Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma

Distinct signatures in the adjuvant and metastatic settings suggest differences in T-cell programs associated with patient outcomes, and support further evaluation of pre-treatment circulating T-cell transcriptional profiles as predictors of ICI response and toxicity in melanoma.

Noah Lepola, C. Dravillas, Shannon Gray et al. · 0 citations
Open access Sep 2026

Tumor γδ T-cell abundance is associated with favorable cancer treatment outcomes

Purpose Clinical response to immune checkpoint blockade (ICB) remains variable. We performed a reference-wide screen to identify immune-cell populations in the tumor microenvironment (TME) associated with benefit across treatment modalities and tumor types. Experimental Design We analyzed pretreatment bulk tumor RNA-se...

Xing-Zhi Niu, Deepali L. Kundnani, Mikaela Dicome et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations
Review Sep 2026

Follicular lymphoma and the microenvironment: potential targets and biomarkers

New insights from single-cell and spatial profiling technologies support a more integrated model of FL biology and provide a foundation for developing microenvironment-directed therapies and precision medicine approaches.

Zhi-Zhang Yang, Stephen Ansell · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.